Market & RegulationInvestment · $2.1B
DeepMind Spinout Isomorphic Labs Raises $2.1B
Siftedhigh confidence
Why it matters
- →Isomorphic Labs is leveraging AI to transform drug discovery, a field traditionally reliant on slower methods.
- →The $2.1 billion funding round indicates strong investor confidence in AI's potential to revolutionize pharmaceuticals.
- →Partnerships with major pharmaceutical companies suggest significant industry interest and potential for impactful collaborations.
Isomorphic Labs, a spinout from DeepMind, has raised $2.1 billion in a Series B funding round led by Thrive Capital. The round also saw participation from the UK’s Sovereign AI fund, Abu Dhabi’s MGX, Alphabet's GV, and Singapore’s Temasek. Founded in 2021, Isomorphic Labs is developing a drug discovery platform using AlphaFold technology to predict protein structures. The company has already partnered with pharmaceutical giants like Eli Lilly and Novartis and is advancing towards pre-clinical trials. This funding highlights the increasing role of AI in transforming drug discovery processes.
Read originalMore from Sifted
More in Market & Regulation
© TechCrunch AIMarket & Regulationbusiness
Microsoft Challenges OpenAI, Anthropic with Own AI Models
Microsoft is positioning itself as a formidable competitor to AI giants OpenAI and Anthropic by promoting its own AI models and infrastructure. CEO Satya Nadella emphasizes the importance of enterprises maintaining control over their AI systems, advocating for a diverse model approach to avoid dependency on any single provider. This strategy is underscored by Microsoft's development of the MAI family of models and the Maya AI chips, which promise cost-effective and efficient performance. By offering a broad catalog of models, Microsoft aims to provide enterprises with flexible and secure AI solutions, challenging the dominance of established AI labs.
TechCrunch AI
Market & Regulationmusic
